six to eight weeks. Hormone therapy is after any hormone Orchiectomy results in primarily for palliation therapy anatomical loss of a of prostate cancer which creative organ; hot flashes is not confined to the therefore osteoporosis prostate for the purpose evaluate under , and loss of muscle of testosterone award SMC. mass deprivation. Hormone therapy may after orchiectomy continue for many impotence Types of hormone years; therefore sterility therapy include review treatment loss of sex drive records for expected after anti-androgen the orchiectomy, duration of therapy removal of testes to treatment, and gastrointestinal prevent testosterone consider upset production permanence. breast tenderness luteinizing hormone gynecomastia releasing hormone decreased libido agonists (LHRH impotence analogs), which can hot flashes lower the testosterone after LHRH analogs as effectively as impotence orchiectomy such as hot flashes, and Lupron (leuprolide) gynecomastia. Zoladex (goserelin), and busrelin estrogens or drugs, which lower the level of testosterone second-line hormonal drugs, which are used when first-line hormone therapy fails anti-androgens, which block the ability of the body to use androgens, such as Eulexin (flutamide) Casodex (bicalutamide), and Nilandron (nilutamide), and combined hormone therapy, which is an anti-androgen combined with
six to eight weeks. Hormone therapy is primarily for palliation of prostate cancer which is not confined to the prostate for the purpose of testosterone deprivation. Types of hormone therapy include orchiectomy, the removal of testes to prevent testosterone production luteinizing hormone releasing hormone agonists (LHRH analogs), which can lower the testosterone as effectively as orchiectomy such as Lupron (leuprolide) Zoladex (goserelin), and busrelin estrogens or drugs, which lower the level of testosterone second-line hormonal drugs, which are used when first-line hormone therapy fails anti-androgens, which block the ability of the body to use androgens, such as Eulexin (flutamide) Casodex (bicalutamide), and Nilandron (nilutamide), and combined hormone therapy, which is an anti-androgen combined with after any hormone therapy hot flashes osteoporosis loss of muscle mass after orchiectomy impotence sterility loss of sex drive after anti-androgen therapy gastrointestinal upset breast tenderness gynecomastia decreased libido impotence hot flashes after LHRH analogs impotence hot flashes, and gynecomastia. Orchiectomy results in anatomical loss of a creative organ; therefore evaluate under , and award SMC. Hormone therapy may continue for many years; therefore review treatment records for expected duration of treatment, and consider permanence.
12-16-15_Key%20Changes_M21-1III_iv_4_SecI.docx